Watch out, Amgen, Allergan and friends. Pharmacy benefit managers are sizing up two up-and-coming sets of new drugs for early pricing pressure. As hepatitis C drugmakers can attest, the consequences can be brutal.Original Article
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
